LBA-001

LBA-001: Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial

Recent News

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology

News

Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer

11/05/2024

Allison Casey ;

According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.

According to a single-center...

11/05/2024

Oncology

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology

News

Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML

10/31/2024

Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...

Gilteritinib maintenance therapy...

10/31/2024

Oncology

News

Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma

10/31/2024

A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.

A safety lead-in for the...

10/31/2024

Oncology

News

Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer

10/31/2024

A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.

A multi-gene target panel NGS...

10/31/2024

Oncology

News

Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis

10/31/2024

According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.

According to a phase 3 trial,...

10/31/2024

Oncology

News

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer

10/29/2024

Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.

Primary results from the...

10/29/2024

Oncology